Changes of serum fibroblast growth factor 23 in patients with end stage renal disease and its clinical significance / 第二军医大学学报

ABSTRACT

Objective: To observe the serum level of fibroblast growth factor-23 (FGF-23) in patients with end stage renal disease (ESRD) and study its association with phosphorus and vitamin D metabolism. Methods: Serum FGF-23 level was determined by enzyme-linked immunosorbent assay (ELISA) in ESRD patients undergoing haemodialysis (HD, n=50) and peritoneal dialysis (PD, n=24) and in twenty healthy controls (control group, n=20). Serum level of 1,25-(OH) 2 VitD was measured by enzyme immunoassay(EIA). Serum intact parathyroid hormone (PTH), creatinine, and calcium and phosphorus were also measured. Results: Serum FGF-23 was obviously higher in HD group([88.51 ± 35.01] ng/L vs [11.76 ± 3.63] ng/L) and PD group([87.85 ± 33.65] ng/L vs [11.76 ± 3.63] ng/L) than in control group. Moreover, the serum level of 1,25-(OH)2 VitD was lower in HD and PD groups than in control group ([19.82 ± 4.99] pmol/L vs [48.37 ± 3.47] pmol/L; [24.31 ± 7.11] pmol/ L vs [48.37 ± 3.47] pmol/L), and the level of 1,25-(OH)2 VitD was much lower in HD group than in PD group. Pearson relativity analysis showed that serum FGF-23 level was positively correlated with serum creatinine, phosphorus, intact PTH and duration of dialysis(P<0.01); and was negatively correlated with 1,25-(OH)2 VitD(P<0.01). Conclusion: Serum FGF-23 is greatly up-regulated in patients with ESRD, and the level of serum 1,25-(OH)2 VitD is down-regulated. The changes of FGF-23 is associated with serum creatinine, phosphorus, intact PTH and 1,25-(OH)2 VitD.